Biocon shares jump 2% after UK approval to diabetes drug : vimarsana.com

So far in 2024, the stock has rallied over 2 percent, marginally outperforming benchmark Nifty which has tisden around 12 percent during this period.

Related Keywords

United Kingdom , India , Biocon Biologics , Siddharth Mittal , National Stock Exchange , Biocon , Healthcare Products Regulatory Agency , Insulin Glargine , Eris Lifesciences ,